ECSP12011992A - Formulación de liberación sostenida - Google Patents
Formulación de liberación sostenidaInfo
- Publication number
- ECSP12011992A ECSP12011992A ECSP12011992A ECSP12011992A EC SP12011992 A ECSP12011992 A EC SP12011992A EC SP12011992 A ECSP12011992 A EC SP12011992A EC SP12011992 A ECSP12011992 A EC SP12011992A
- Authority
- EC
- Ecuador
- Prior art keywords
- sustained release
- release formulation
- salt
- present
- compound
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000013268 sustained release Methods 0.000 title abstract 4
- 239000012730 sustained-release form Substances 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229920001577 copolymer Polymers 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- KAHDONZOCXSKII-NJVVDGNHSA-N kisspeptin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)O)C1=CN=CN1 KAHDONZOCXSKII-NJVVDGNHSA-N 0.000 abstract 1
- 230000007721 medicinal effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a una formulación de liberación sostenida que comprende un derivado de metastina y un copolímero de ácido láctico-ácido glicólico que tiene un peso molecular peso promedio de aproximadamente 5.000 a aproximadamente 40.000 o una sal del mismo. La formulación de liberación sostenida de la presente invención libera en forma lenta y estable el compuesto (I) o una sal del mismo durante mucho tiempo y ejerce un efecto medicinal del compuesto (I) o una sal del mismo durante un período de tiempo extenso. Además, la formulación de liberación sostenida de la presente invención, que mejora la conveniencia del paciente reduciendo el número de episodios de administración, es una excelente formulación como una medicina clínica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009290364 | 2009-12-22 | ||
| JP2010144793 | 2010-06-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP12011992A true ECSP12011992A (es) | 2012-07-31 |
Family
ID=43743497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP12011992 ECSP12011992A (es) | 2009-12-22 | 2012-06-21 | Formulación de liberación sostenida |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20120302508A1 (es) |
| EP (1) | EP2515878B1 (es) |
| JP (3) | JP2013514968A (es) |
| KR (1) | KR20120098906A (es) |
| CN (2) | CN107412725A (es) |
| AR (1) | AR079657A1 (es) |
| AU (1) | AU2010336168A1 (es) |
| BR (1) | BR112012014947A2 (es) |
| CA (1) | CA2785021C (es) |
| CO (1) | CO6551752A2 (es) |
| CR (1) | CR20120290A (es) |
| DO (1) | DOP2012000171A (es) |
| EA (1) | EA020865B1 (es) |
| EC (1) | ECSP12011992A (es) |
| ES (1) | ES2434315T3 (es) |
| IL (1) | IL219967A0 (es) |
| MA (1) | MA33910B1 (es) |
| MX (1) | MX2012006441A (es) |
| NZ (1) | NZ600157A (es) |
| PE (1) | PE20121481A1 (es) |
| PH (1) | PH12012501255A1 (es) |
| SG (1) | SG181436A1 (es) |
| TN (1) | TN2012000255A1 (es) |
| TW (1) | TW201125575A (es) |
| UY (1) | UY33127A (es) |
| WO (1) | WO2011078394A2 (es) |
| ZA (1) | ZA201203775B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012032544A2 (pt) * | 2010-06-25 | 2016-10-11 | Takeda Pharmaceutical | formulação de liberação prolongada, uso de um composto, e, método para produzir a formulação de liberação prolongada. |
| TW201618783A (zh) | 2014-08-07 | 2016-06-01 | 艾森塔製藥公司 | 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法 |
| TWI855377B (zh) | 2016-09-30 | 2024-09-11 | 瑞士商麥歐文科學有限公司 | 治療女性不孕症之方法 |
| WO2022163966A1 (ko) * | 2021-01-29 | 2022-08-04 | 주식회사 티온랩테라퓨틱스 | 초기 방출 제어된 데포 조성물 및 이의 제조방법 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9211268D0 (en) * | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
| FR2693905B1 (fr) * | 1992-07-27 | 1994-09-02 | Rhone Merieux | Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues. |
| US20030026844A1 (en) * | 2000-04-18 | 2003-02-06 | Hee-Yong Lee | Injectable sustained release pharmaceutical composition and processes for preparing the same |
| AR023940A1 (es) * | 2000-05-03 | 2002-09-04 | Eriochem Sa | Procedimiento para la produccion de microcapsulas de liberacion prolongada de peptidos solubles en agua |
| ATE506942T1 (de) * | 2000-09-01 | 2011-05-15 | Palmaya Pty Ltd | Pharmazeutische zubereitung und methode diese zu verabreichen |
| EP1346722B1 (en) * | 2000-12-01 | 2008-12-10 | Takeda Pharmaceutical Company Limited | Method for producing preparation containing bioactive substance |
| WO2002085399A1 (fr) * | 2001-04-20 | 2002-10-31 | Takeda Chemical Industries, Ltd. | Preparations contenant un peptide |
| JP2003002841A (ja) * | 2001-04-20 | 2003-01-08 | Takeda Chem Ind Ltd | ペプチド含有製剤 |
| CA2511858A1 (en) * | 2002-12-26 | 2004-07-29 | Takeda Pharmaceutical Company Limited | Metastin derivative and use thereof |
| JP4346650B2 (ja) | 2004-06-25 | 2009-10-21 | 武田薬品工業株式会社 | メタスチン誘導体およびその用途 |
| TW200613012A (en) * | 2004-07-02 | 2006-05-01 | Takeda Pharmaceuticals Co | Sustained-release composition, process for producing the same and use of the same |
| CN1923284A (zh) * | 2005-08-30 | 2007-03-07 | 孔庆忠 | 抗癌药物缓释注射剂及其应用 |
| US8404643B2 (en) * | 2005-12-22 | 2013-03-26 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| TWI386417B (zh) * | 2005-12-22 | 2013-02-21 | Takeda Pharmaceutical | 轉移抑素衍生物及其用途 |
| ZA200805393B (en) * | 2005-12-22 | 2009-12-30 | Takeda Pharmaceutical | Metastin derivatives and use thereof |
| GEP20125597B (en) * | 2006-12-18 | 2012-08-10 | Takeda Pharmaceutical | Sustained-release composition and production method thereof |
| US20110118172A1 (en) * | 2008-04-24 | 2011-05-19 | Takeda Pharmaceutical Company Limited | Metastin derivative and use thereof |
| PE20110939A1 (es) * | 2008-12-29 | 2012-01-19 | Takeda Pharmaceutical | Agente preventivo/terapeutico contra el cancer |
| SI2603600T1 (sl) * | 2010-08-13 | 2019-04-30 | Aileron Therapeutics, Inc. | Peptidomimetični makrocikli |
-
2010
- 2010-12-21 EA EA201290372A patent/EA020865B1/ru not_active IP Right Cessation
- 2010-12-21 JP JP2012528582A patent/JP2013514968A/ja active Pending
- 2010-12-21 PE PE2012000862A patent/PE20121481A1/es not_active Application Discontinuation
- 2010-12-21 MA MA35045A patent/MA33910B1/fr unknown
- 2010-12-21 KR KR1020127019082A patent/KR20120098906A/ko not_active Withdrawn
- 2010-12-21 EP EP10805747.2A patent/EP2515878B1/en active Active
- 2010-12-21 UY UY33127A patent/UY33127A/es not_active Application Discontinuation
- 2010-12-21 WO PCT/JP2010/073665 patent/WO2011078394A2/en not_active Ceased
- 2010-12-21 MX MX2012006441A patent/MX2012006441A/es unknown
- 2010-12-21 TW TW099144892A patent/TW201125575A/zh unknown
- 2010-12-21 CN CN201610917016.8A patent/CN107412725A/zh active Pending
- 2010-12-21 CA CA2785021A patent/CA2785021C/en active Active
- 2010-12-21 BR BR112012014947A patent/BR112012014947A2/pt not_active IP Right Cessation
- 2010-12-21 NZ NZ600157A patent/NZ600157A/xx not_active IP Right Cessation
- 2010-12-21 US US13/517,202 patent/US20120302508A1/en not_active Abandoned
- 2010-12-21 ES ES10805747T patent/ES2434315T3/es active Active
- 2010-12-21 AR ARP100104811A patent/AR079657A1/es not_active Application Discontinuation
- 2010-12-21 CN CN2010800587326A patent/CN102665690A/zh active Pending
- 2010-12-21 SG SG2012037768A patent/SG181436A1/en unknown
- 2010-12-21 AU AU2010336168A patent/AU2010336168A1/en not_active Abandoned
- 2010-12-21 PH PH1/2012/501255A patent/PH12012501255A1/en unknown
-
2012
- 2012-05-23 ZA ZA2012/03775A patent/ZA201203775B/en unknown
- 2012-05-24 IL IL219967A patent/IL219967A0/en unknown
- 2012-05-24 TN TNP2012000255A patent/TN2012000255A1/en unknown
- 2012-05-30 CR CR20120290A patent/CR20120290A/es not_active Application Discontinuation
- 2012-06-18 DO DO2012000171A patent/DOP2012000171A/es unknown
- 2012-06-21 EC ECSP12011992 patent/ECSP12011992A/es unknown
- 2012-06-22 CO CO12104834A patent/CO6551752A2/es unknown
-
2015
- 2015-08-24 JP JP2015164390A patent/JP6472730B2/ja not_active Expired - Fee Related
-
2017
- 2017-03-21 JP JP2017054363A patent/JP2017160201A/ja not_active Withdrawn
- 2017-11-10 US US15/809,459 patent/US20180228732A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA107112C2 (uk) | Активатори розчинної гуанілатциклази | |
| BR112013027674A2 (pt) | "usos de composições de nanopartículas, composições compreendendo as referidas nanopartículas e cateter com uma agulha". | |
| BR112014029209A2 (pt) | formulação para implante de risperidona ou paliperidona | |
| NI201200089A (es) | INHIBIDORES DE N1 - PIRAZOLOESPIROCETONA ACETIL - CoA CARBOXILASA. | |
| DOP2011000343A (es) | Derivados de piridina tieno [2,3-b] como inhibidores de replicacion viral | |
| DOP2012000011A (es) | Formulacion farmaceutica | |
| MX2013002453A (es) | Analogos deuterados de pridopidina utiles como estabilizadores dopaminergicos. | |
| ECSP15039103A (es) | Formulación de liberación sostenida de mosapride que proporciona efectos farmacológicos y clínicos con administración una vez al día | |
| CR20110568A (es) | Guía con sensor | |
| GT201000182A (es) | Regimen de dosificacion asociado con ésteres de paliperidona inyectables de acción prolongada | |
| BRPI1002601E2 (pt) | composição nanoestruturada de uso veterinário para administração de fármacos | |
| CU20080114A7 (es) | Emulsión intravenosa de butilftalida y aplicación de la misma | |
| MX2014003334A (es) | Derivados de tio novedosos que tienen lactamas como potentes inhibidores de hdac y sus usos como medicamentos. | |
| BR112013016770A2 (pt) | formulação farmacêutica, fármaco biofarmacêutico, seringa ou caneta pré-preenchida, uso de uma formulação farmacêutica | |
| SV2011003907A (es) | Composiciones antimicrobianas | |
| AR069674A1 (es) | Nanoparticulas que contienen farmaco | |
| JP2012517449A5 (es) | ||
| CO6331308A2 (es) | Derivados de carboxamidaindazol con actividad sobre el receptor cb1 y composiciones farmaceuticas que los comprenden | |
| AR077125A1 (es) | Combinaciones farmaceuticas utiles para tratar el vhc | |
| AR077138A1 (es) | Composiciones farmaceuticas utiles para tratar el vhc | |
| ECSP12011992A (es) | Formulación de liberación sostenida | |
| BR112015014433A2 (pt) | compostos tricíclicos | |
| DOP2012000304A (es) | Formulacion de liberacion sostenida | |
| BR112015019307A2 (pt) | derivados de ácido butanoico substituído com bisfenila como inibidores de nep com eficácia in vivo melhorada | |
| PE20130308A1 (es) | Metodos para tratar infecciones bacterianas recurrentes |